News
CASI
2.500
-3.47%
-0.090
CASI Pharmaceuticals Secures Interim Relief in Juventas Dispute
TipRanks · 4d ago
Weekly Report: what happened at CASI last week (0203-0207)?
Weekly Report · 4d ago
Weekly Report: what happened at CASI last week (0127-0131)?
Weekly Report · 02/03 11:00
Weekly Report: what happened at CASI last week (0120-0124)?
Weekly Report · 01/27 11:03
CASI Pharmaceuticals Faces Asset Freezing Amid Arbitration Dispute
TipRanks · 01/21 13:27
Weekly Report: what happened at CASI last week (0113-0117)?
Weekly Report · 01/20 10:55
Weekly Report: what happened at CASI last week (0106-0110)?
Weekly Report · 01/13 10:56
Casi Pharmaceuticals announces first patient dosed in Phase 1/2 trial of CID-103
TipRanks · 01/06 13:30
Weekly Report: what happened at CASI last week (1230-0103)?
Weekly Report · 01/06 11:03
Weekly Report: what happened at CASI last week (1223-1227)?
Weekly Report · 12/30/2024 10:58
BRIEF-CASI Pharmaceuticals Announces Clinical Hold Of CID-103
Reuters · 12/26/2024 15:41
BUZZ-Casi Pharmaceuticals falls after FDA puts experimental antibody drug on hold
Reuters · 12/26/2024 14:23
CASI Pharmaceuticals Faces Clinical Hold on CID-103 by FDA
TipRanks · 12/26/2024 13:57
Weekly Report: what happened at CASI last week (1216-1220)?
Weekly Report · 12/23/2024 11:04
Casi Pharmaceuticals files $200M mixed securities shelf
TipRanks · 12/20/2024 22:40
BRIEF-Casi Pharmaceuticals Inc Files For Mixed Shelf Offering Of Up To $200 Million- SEC Filing
Reuters · 12/20/2024 22:29
CASI Pharmaceuticals Faces Evomela® License Termination Dispute
TipRanks · 12/16/2024 13:27
Weekly Report: what happened at CASI last week (1209-1213)?
Weekly Report · 12/16/2024 11:05
Weekly Report: what happened at CASI last week (1202-1206)?
Weekly Report · 12/09/2024 11:03
Weekly Report: what happened at CASI last week (1125-1129)?
Weekly Report · 12/02/2024 11:03
More
Webull provides a variety of real-time CASI stock news. You can receive the latest news about Casi Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About CASI
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.